Jade Biosciences, Inc.
JBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$644.36M
Close$
$2.80
86.9% downside
Current Fair Value
86.9% downsideOvervalued by 86.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $644.36 Million |
|---|---|
| Enterprise Value | $589.95 Million |
| Dividend Yield | $2.40 (-) |
| Earnings per Share | $-4.06 |
| Beta | 1.43 |
| Outstanding Shares | 57,777,165 |
Return
| Return on Equity | -55.74% |
|---|---|
| Return on Assets | -51.74% |
| Return on Invested Capital | -52.44% |
Valuation & Multiples
| P/E Ratio | -6.76 |
|---|---|
| PEG | -0.45 |
| Price to Sales | - |
| Price to Book Ratio | 4.27 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.79 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 624.41% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.58%▼ 83.69% |
|---|---|
| Total Invested | $32.92M▼ 95.30% |
| Investors Holding | 23▼ 100.00% |
ESG Score
No data
About Jade Biosciences, Inc.
50 employees
CEO: Tom Frohlich Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) ...